Accelerate to discover

Back to filter

Related topics

The roles of preclinical optical imaging in cancer research

Spectral Instruments Imaging

Sep 22, 2021

Watch the last Spectral Instrument Imaging webinar with Dr. Michael Henry who will shares key data sets from his work...

See What's Possible with the PippinHT

Sage Science

Sep 14, 2021

Programmable DNA size selection enables new discoveries by helping optimize the library detected by a sequencer. That’s...

Magnetic resonance elastography techniques and preclinical applications

Bruker Biospin

Sep 14, 2021

It has been known for centuries that tissue stiffness can change in the presence of disease, but quantifying such...

Ex Vivo dental imaging is directly translatable to the clinic

Bruker Biospin

Sep 14, 2021

Although patients are too large in size for preclinical microCT scanners, it still has a big significance in clinical...

Sep 28, 2021

IncuCyte live cell analysis system for 3D Organoids discovery

Sartorius & Essen BioScience

Sep 10, 2021

Live-Cell Analysis has revolutionized numerous studies, with a wide selection of applications namely 3D Tumour Spheroid...

Blood-Brain Barrier (BBB) - Pathophysiology in ischemic stroke

RWD

Aug 27, 2021

In-depth Understanding of Blood-Brain Barrier (BBB)

Introducing New Aura 4.0 software

Spectral Instruments Imaging

Aug 27, 2021

With new features for both acquisition & analysis Aura Software enables you to capture and analyze your data quickly,...

Sep 28, 2021

Micro-CT user meeting 2021

Bruker Biospin

Aug 19, 2021

Year after year, the Micro-CT User meeting showcases state-of-the-art applications in both life and material sciences,...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey